TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30307945

Group type: EXPERIMENTAL
Intervention: Protein-calorie supplement (PCS) plus micronutrient supplement (MNS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Micronutrient supplement (MNS) alone
Number of subjects: 96
Study: 28012242

Group type: EXPERIMENTAL
Intervention: Nonivamide (0.15 mg per day in 450 mL of a milk shake)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 19
Study: 26602097

Group type: EXPERIMENTAL
Intervention: Cancer vaccine prepared from autologous dendritic cells and uveal melanoma RNA
Number of subjects: 0
Study: 23177917

Group type: EXPERIMENTAL
Intervention: Home use of mifepristone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Office administration of mifepristone
Number of subjects: 301
Study: 21598413

Group type: EXPERIMENTAL
Intervention: Panax ginseng extract (20 g/day mixed with 200 ml of water, three times/day for seven days prior and four days after exercise)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Panax ginseng extract
Number of subjects: 18
Study: 18283204

Group type: EXPERIMENTAL
Intervention: 1500 mg of oral glucosamine sulfate once daily
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 16571285

Group type: EXPERIMENTAL
Intervention: SFI pre-treatment with GP regimen
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SFI post-treatment with GP regimen
Number of subjects: 34

Group type: COMPARATOR
Intervention: GP chemotherapy alone
Number of subjects: 34
Study: 14763252

Group type: EXPERIMENTAL
Intervention: Combined kineso- and psychotherapy (Group 1, 23 patients)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard physical therapy and explanatory psychotherapy (Group 2, 18 patients)
Number of subjects: 41
Study: 10873968

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for three months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 9175690

Group type: EXPERIMENTAL
Intervention: Paternal lymphocytes immunization
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no paternal lymphocytes immunization)
Number of subjects: 104
Study: 1487626

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 4
Study: 3942304

Group type: EXPERIMENTAL
Intervention: 5 mg epidural morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg epidural morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (0 mg epidural morphine)
Number of subjects: 0
Study: 30022244

Group type: EXPERIMENTAL
Intervention: Outpatient spa therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inpatient spa therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Etodolac treatment
Number of subjects: 150
Study: 26850424

Group type: EXPERIMENTAL
Intervention: Corticosteroid in periarticular injection
Number of subjects: 77

Group type: COMPARATOR
Intervention: No corticosteroid in periarticular injection
Number of subjects: 77
Study: 24965739

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=126)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment (n=117)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Modic type I
Number of subjects: 243

Group type: COMPARATOR
Intervention: Modic type II-III
Number of subjects: 243

Group type: COMPARATOR
Intervention: Patients without Modic changes
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Modic size L1-S1
Number of subjects: 243
Study: 23190905

Group type: EXPERIMENTAL
Intervention: Comprehensive self management program (4 tailored sessions with ongoing telephone support)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Routine monitoring (2-4 structured consultations a year)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care (contacts with the general practitioner at the patients' own initiative)
Number of subjects: 165
Study: 20347369

Group type: EXPERIMENTAL
Intervention: 150-mg monthly oral ibandronate
Number of subjects: 323
Study: 18394048

Group type: EXPERIMENTAL
Intervention: levetiracetam (LEV) 3000 mg
Number of subjects: 38
Study: 17262131

Group type: EXPERIMENTAL
Intervention: Pulp vitality group (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pulp necrosis group (n=9)
Number of subjects: 18
Study: 12961817

Group type: EXPERIMENTAL
Intervention: Counseling sessions conducted by minimally trained community counselors (8 sessions)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 366
Study: 11034121

Group type: EXPERIMENTAL
Intervention: Double-textured prototype manual toothbrush
Number of subjects: 15

Group type: COMPARATOR
Intervention: Branded toothbrushes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: One of the prototype brushes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: One of the branded brushes
Number of subjects: 15

Group type: COMPARATOR
Intervention: All brushes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Professional brushing method
Number of subjects: 15
Study: 9373766

Group type: EXPERIMENTAL
Intervention: High soluble fibre diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: High insoluble fibre diet
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: FABP2 T54 allele
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dietary soluble fibre
Number of subjects: 43
Study: 1383816

Group type: EXPERIMENTAL
Intervention: 5 mg of finasteride per day
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: 1 mg of finasteride per day
Number of subjects: 895

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study: 3894279

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Novantrone (mitoxantrone) and 5‐fluorouracil (CNF)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cyclophosphamide, Adriamycin (doxorubicin) and 5‐fluorouracil (CAF)
Number of subjects: 115
Study: 30824040

Group type: EXPERIMENTAL
Intervention: Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Tacrolimus, methotrexate, and bortezomib
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Tacrolimus, methotrexate, and maraviroc
Number of subjects: 273

Group type: COMPARATOR
Intervention: Tacrolimus and methotrexate (control group)
Number of subjects: 273
Study: 30369135

Group type: EXPERIMENTAL
Intervention: 4HPR group
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 4HPR-L group
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 4HPR-LM + ultrasound group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 26931192

Group type: EXPERIMENTAL
Intervention: Probiotics (bifidobacillus and lactobacillus) administered once daily by nasogastric tube from the third day of life
Number of subjects: 714

Group type: COMPARATOR
Intervention: No probiotics (control group)
Number of subjects: 714
Study: 25304947

Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 252

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 252
Study: 21752491

Group type: EXPERIMENTAL
Intervention: Adalimumab continuous therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab after 16 weeks of placebo therapy
Number of subjects: 0
Study: 19887933

Group type: EXPERIMENTAL
Intervention: Industry-funded trials
Number of subjects: 346

Group type: COMPARATOR
Intervention: Non-industry funded trials
Number of subjects: 346
Study: 17470079

Group type: EXPERIMENTAL
Intervention: Programme control/key views (PKV)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Programme control/multiple views (PMV)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Learner control/multiple views (LMV)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Learner control/key views (LKV)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No learner control/key views (SKV)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low learner control/key views (PKV)
Number of subjects: 240
Study: 15326237

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 42 days, followed by forced dose escalation to 10 mg/day)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 11273584

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)/leucovorin
Number of subjects: 2542
Study: 9751447

Group type: EXPERIMENTAL
Intervention: Hydrocolloidal-based matrix tablet (optimized formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing once-daily diltiazem HC1 product (Dilacor XR 240mg)
Number of subjects: 0
Study: 7917729

Group type: EXPERIMENTAL
Intervention: Propofol 8 mg kg‐1 h‐1 followed by 4 mg kg‐1 h‐1 and fentanyl 15 micrograms kg‐1 (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 3‐6 mg and fentanyl 60 micrograms kg‐1 (group 2)
Number of subjects: 0
Study: 3279089

Group type: EXPERIMENTAL
Intervention: 5-Methoxypsoralen (5-MOP) administered at a high oral dosage (doubled from standard dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-Methoxypsoralen (8-MOP)
Number of subjects: 0
Study: 30847444

Group type: EXPERIMENTAL
Intervention: Oral piracetam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral betahistine
Number of subjects: 100
Study: 29202261

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 100
Study: 26551364

Group type: EXPERIMENTAL
Intervention: Resin composite strip crown
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Preveneered stainless steel crown (PVSSC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prefabricated primary zirconia crown
Number of subjects: 39

Group type: COMPARATOR
Intervention: Overall satisfaction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Durability of resin strip crowns
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Colour of PVSSC
Number of subjects: 39
Study: 22964452

Group type: EXPERIMENTAL
Intervention: 6mg/kg anhydrous caffeine fasted
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 9mg/kg anhydrous caffeine fasted
Number of subjects: 14

Group type: COMPARATOR
Intervention: 6mg/kg anhydrous caffeine fed
Number of subjects: 14

Group type: COMPARATOR
Intervention: 9mg/kg anhydrous caffeine fed
Number of subjects: 14
Study: 21978872

Group type: EXPERIMENTAL
Intervention: OPCAB-converted patients
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Elective OPCAB conversions
Number of subjects: 2203
Study: 19203715

Group type: EXPERIMENTAL
Intervention: Se-enriched yeast (200 microg Se/day)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 16965415

Group type: EXPERIMENTAL
Intervention: Mupirocin plus hydrocortisone butyrate ointment
Number of subjects: 327

Group type: COMPARATOR
Intervention: Vehicle ointment plus hydrocortisone butyrate ointment
Number of subjects: 327
Study: 15373933

Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW) 900 mg day(‐1) for 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quazepam
Number of subjects: 13
Study: 11318297

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 30

Group type: COMPARATOR
Intervention: pilocarpine 4%
Number of subjects: 30
Study: 9253329

Group type: COMPARATOR
Intervention: GH alone (0.3 IU/kg.day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of IGF‐I (80 micrograms/kg.day) and GH (0.3 IU/kg.day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8323473

Group type: EXPERIMENTAL
Intervention: Combination therapy with dipyridamole (75 mg three times a day) and aspirin (330 mg three times a day)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 3103983

Group type: EXPERIMENTAL
Intervention: Combined blunt spatula debridement and trifluridine therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Trifluridine alone
Number of subjects: 31
Study: 31693994

Group type: EXPERIMENTAL
Intervention: Community‐Based Participatory Research intervention (4-week duration)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Community‐Based Participatory Research intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 39
Study: 30496408

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 0
Study: 27929674

Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Empagliflozin (all doses)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 25985246

Group type: EXPERIMENTAL
Intervention: PDA-001 (8 units, 1.5 × 10^6 cells per unit) in phase 1b study
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PDA-001 (1 unit or 4 units, 2 infusions 1 week apart) in phase 2a study
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PDA-001 (1 unit or 4 units)
Number of subjects: 50
Study: 24330604

Group type: EXPERIMENTAL
Intervention: Smartphone application intervention for physical activity adherence
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (physical activity and educational advice)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no smartphone application)
Number of subjects: 40
Study: 21224289

Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion
Number of subjects: 13
Study: 19202720

Group type: EXPERIMENTAL
Intervention: Interactive behavioral condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health-based education (control) condition
Number of subjects: 60
Study: 17062470

Group type: EXPERIMENTAL
Intervention: Phototherapy with chest shield
Number of subjects: 54

Group type: COMPARATOR
Intervention: Phototherapy without chest shield
Number of subjects: 54
Study: 16036075

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 11885184

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated grooved implants
Number of subjects: 149

Group type: COMPARATOR
Intervention: Preoperative antibiotics
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Implant length
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mean stability values (PTVs)
Number of subjects: 149
Study: 8738691

Group type: EXPERIMENTAL
Intervention: pH-stat
Number of subjects: 45

Group type: COMPARATOR
Intervention: alpha-stat
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Head-injured patients (HI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 45
Study: 1540597

Group type: EXPERIMENTAL
Intervention: Diltiazem (30 mg three times daily increasing to 60 mg three times daily at 1 month)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No calcium blocker (Control)
Number of subjects: 69
Study: 4048359

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 28641469

Group type: EXPERIMENTAL
Intervention: Counselling (6 group sessions, twice per week for 3 weeks)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (no counselling)
Number of subjects: 152
Study: 26794922

Group type: EXPERIMENTAL
Intervention: Norwich Patellar Instability (NPI) Score
Number of subjects: 50
Study: 22377774

Group type: EXPERIMENTAL
Intervention: Mahjong
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 36

Group type: COMPARATOR
Intervention: Handicrafts (placebo)
Number of subjects: 36
Study: 20374034

Group type: EXPERIMENTAL
Intervention: Neoadjuvant aromatase inhibitors (AI) for 3 months
Number of subjects: 14
Study: 17826268

Group type: EXPERIMENTAL
Intervention: MIS mini‐incision mid‐vastus (mini)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MIS side‐cutting (side cut)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional (control)
Number of subjects: 90
Study: 16062074

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m2 every 21 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not applicable, as the phase II part was canceled)
Number of subjects: 14
Study: 11863244

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 19
Study: 12370869

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 9791043

Group type: EXPERIMENTAL
Intervention: Spectral analysis method
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Valsalva method
Number of subjects: 26

Group type: COMPARATOR
Intervention: Phenylephrine method
Number of subjects: 26
Study: 7997500

Group type: EXPERIMENTAL
Intervention: Newly designed partial subperiosteal implants
Number of subjects: 52

Group type: COMPARATOR
Intervention: Classical design partial subperiosteal implants
Number of subjects: 52
Study: 3137024

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31200668

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy from a psychiatric nurse
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-specific support given by volunteers
Number of subjects: 450

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 450
Study: 29798368

Group type: EXPERIMENTAL
Intervention: Intratympanic injection of budesonide (BUD) 0.5 mg/ml
Number of subjects: 180

Group type: COMPARATOR
Intervention: Intratympanic injection of dexamethasone (DEX) 5 mg/ml
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NS) solution (1 ml)
Number of subjects: 180
Study: 25100232

Group type: EXPERIMENTAL
Intervention: Participants informed at encoding of the context in which cues were to appear
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants not informed at encoding of the context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task interference during the third phase with specified cue context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex-Gaussian parameter estimates
Number of subjects: 0
Study: 22939855

Group type: EXPERIMENTAL
Intervention: Superior cavopulmonary anastomosis
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Age at superior cavopulmonary anastomosis
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Superior cavopulmonary anastomosis type, valve regurgitation, ventricular ejection fraction, and ventricular end-diastolic pressure
Number of subjects: 193
Study: 21977965

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg once daily
Number of subjects: 170
Study: 18326612

Group type: EXPERIMENTAL
Intervention: 3 mg Zn as zinc sulfate
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: 7 mg Zn as zinc sulfate
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: 10 mg Zn as zinc sulfate
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: 10 mg Zn + 0.5 mg Cu as copper sulfate
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 17726807

Group type: EXPERIMENTAL
Intervention: Yasmin (3 mg Drospirenone and 30 microg ethinylestradiol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meliane (75 microg gestodene + 20 microg ethinylestradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yasmin and Meliane
Number of subjects: 0
Study: 14638387

Group type: EXPERIMENTAL
Intervention: Remacemide and co‐enzyme Q(10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study: 10883875

Group type: EXPERIMENTAL
Intervention: SRP+Metro (subgingival scaling and root planing with metronidazole 25% dental gel)
Number of subjects: 59

Group type: COMPARATOR
Intervention: SRP (subgingival scaling and root planing without metronidazole)
Number of subjects: 59
Study: 8615309

Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium scintigraphy measuring left ventricular cavity size
Number of subjects: 335

Group type: COMPARATOR
Intervention: Normal perfusion patterns
Number of subjects: 335
Study: 1426202

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 micrograms daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bronchodilator therapy alone (salbutamol or ipratropium bromide)
Number of subjects: 56
Study: 31200648

Group type: EXPERIMENTAL
Intervention: Online interventions (specific types not detailed) in Study 1
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: Online interventions (specific types not detailed) in Study 2
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Control group (no intervention) in both studies
Number of subjects: 1389
Study: 30295170

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Satisfaction with daily activities
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Diabetes knowledge
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Participation in daily activities
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Diabetes distress
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Life satisfaction
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 81
Study: 26381427

Group type: EXPERIMENTAL
Intervention: ondansetron and dexamethasone (low-risk patients)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: aprepitant, extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (level 0)
Number of subjects: 152
Study: 25038148

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) infusion during dynamic handgrip exercise (15% maximal effort)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) infusion
Number of subjects: 39